Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23293044 | 0.83 | TSHR (0.42) | MEN1USP2ABCB11LMNACYP1A2 | |
| SCHEMBL6948871 | 0.79 | PRKCA (0.31) | — | |
| SCHEMBL6948877 | 0.79 | PRKCA (0.31) | — | |
| SCHEMBL8990557 | 0.79 | MEN1 (0.33) | MEN1USP2ABCB11LMNACYP1A2 | |
| SCHEMBL18260177 | 0.78 | TSHR (0.31) | TSHR | |
| SCHEMBL6007742 | 0.77 | PRKCA (0.43) | TSHR | |
| Ammonia Solution, Strong SCHEMBL28497725 | 0.75 | PRKCA (0.42) | TSHR | |
| SCHEMBL1254813 | 0.73 | ELANE (0.31) | TSHR | |
| SCHEMBL194990 | 0.71 | — | — | |
| SCHEMBL21641901 | 0.70 | TSHR (0.32) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040208823-A1 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | LANTHEUS MEDICAL IMAGING, INC. | 2004-10-21 | — | — | US | claimed |
| US-6348504-B1 | COMPOUNDS WITH AMIDINE OR GUANIDINE GROUPS AND CARBOXY OR ESTER GROUPS THROMBOLYTICS AND/OR FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS. | DUPONT PHARMACEUTICALS COMPANY | 2002-02-19 | — | — | US | claimed |
| US-6322770-B1 | FOR DIAGNOSIS AND TREATMENT OF CANCER, IMAGING TUMORS, MONITORING THERAPEUTIC ANGIOGENESIS TREATMENT AND DESTRUCTION OF NEW ANGIOGENIC VASCULATURE; COMPRISED OF TARGETING MOIETY THAT BINDS TO RECEPTOR AND RADIOISOTOPE | DUPONT PHARMACEUTICALS COMPANY | 2001-11-27 | — | — | US | claimed |
| EP-0832077-B1 | IMPROVED ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | DU PONT PHARM CO (US) | 2001-11-14 | — | — | EP | claimed |
| US-5961483-A | Iontophoretic delivery of cell adhesion inhibitors | COLLATERAL AGENTS, LLC | 1999-10-05 | — | — | US | claimed |
| EP-0920345-A4 | IONTOPHORETIC DELIVERY OF CELL ADHESION INHIBITORS | VYTERIS INC (US) | 2006-05-10 | — | — | EP | disclosed |
| US-6348504-B1 | COMPOUNDS WITH AMIDINE OR GUANIDINE GROUPS AND CARBOXY OR ESTER GROUPS THROMBOLYTICS AND/OR FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS. | DUPONT PHARMACEUTICALS COMPANY | 2002-02-19 | — | — | US | disclosed |
| US-6319937-B1 | INHIBITION OF PLATELET AGGREGATION, AS THROMBOLYTICS, AND/OR TREATMENT OF THROMBOEMBOLIC DISORDERS. | DUPONT PHARMACEUTICALS COMPANY | 2001-11-20 | — | — | US | disclosed |
| US-5961483-A | Iontophoretic delivery of cell adhesion inhibitors | COLLATERAL AGENTS, LLC | 1999-10-05 | — | — | US | disclosed |
| US-5935598-A | DEVICE FOR NON-INVASIVE ADMINISTRATION OF A CELL ADHESION RECEPTOR ANTAGONIST TO A MAMMAL; CURRENT DISTRIBUTING MEMBER, IONIZABLE ANTAGONIST RESERVOIR, ELECTROLYTE RESERVOIR, POWDER SOURCE; TREATING THROMBOSIS, ANTICOAGULANTS | BECTON DICKINSON RESEARCH CENTER (US) | 1999-08-10 | — | — | US | disclosed |
| EP-0920345-A1 | IONTOPHORETIC DELIVERY OF CELL ADHESION INHIBITORS | Becton Dickinson and Company (US) | 1999-06-09 | — | — | EP | disclosed |
| WO-1997048444-A1 | IONTOPHORETIC DELIVERY OF CELL ADHESION INHIBITORS | BECTON DICKINSON AND COMPANY (US) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997048443-A1 | IONTOPHORETIC DELIVERY OF CELL ADHESION INHIBITORS | BECTON DICKINSON AND COMPANY (US) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040208823-A1 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | TNNI3, ASGR1, TNNT2 | MEN1 734/4885USP2 4199/4885ABCB11 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.